Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis

Pediatr Pulmonol. 2022 Dec;57(12):3174-3176. doi: 10.1002/ppul.26116. Epub 2022 Aug 24.

Authors

Benjamin C Lyman¹, Jessica Seay¹, Casey Contreary¹, Adrienne P Savant², Mary Lynn Dell², George C Hescock¹

Affiliations

¹ Department of Pediatrics, LSU Health New Orleans, New Orleans, Louisiana, USA.
² Department of Pediatrics, Tulane University, New Orleans, Louisiana, USA.

PMID: 35962539
DOI: 10.1002/ppul.26116

No abstract available

Keywords: CFTR-modulator; cystic fibrosis; elexacaftor-tezacaftor-ivacaftor; ingestion; mental health.

MeSH terms

Adolescent
Aminophenols / therapeutic use
Benzodioxoles / therapeutic use
Chloride Channel Agonists / therapeutic use
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / drug therapy
Drug Combinations
Female
Humans
Mutation
Pyrazoles / therapeutic use

Substances

ivacaftor
tezacaftor
elexacaftor
Aminophenols
Benzodioxoles
Drug Combinations
Pyrazoles
Cystic Fibrosis Transmembrane Conductance Regulator
Chloride Channel Agonists